I think that it absolutely does, but it's a different patient set, a different treatment regimen, and I'm not a doctor. I don't think it's unreasonable to draw that conclusion though, particularly since the rebounders witnessed in the P2 trials occurred well before 25 weeks. Personally, I take it as a significant feather in the cap, and think that overall risk to mono and the company stepped down quite a bit yesterday.
That's just my opinion though. And failing the treatment regimen or not, combo is not mono, so it's definitely not 100% apples to apples.
News 
Market Data 
Discover 
